Skip to main content
Premium Trial:

Request an Annual Quote

Hardy Diagnostics to Distribute NG Biotech Test for Detecting Antibiotic-Resistance Enzymes

NEW YORK – Hardy Diagnostics announced on Thursday a deal with NG Biotech to distribute that firm's NG-Test Carba 5 for the detection and differentiation of the five most common carbapenemases from bacterial culture of Enterobacterales and Pseudomonas aeruginosa.

The carbapenemases detected by NG-Test Carba 5 are KPC, OXA-48-like, VIM, IMP, and NDM. It provides results in 15 minutes, Santa Maria, California-based Hardy said in a statement, adding the test saves microbiologists time by "simplifying the process of testing for these resistance enzymes." 

Financial and other terms of the agreement were not disclosed.

Hardy manufactures and distributes medical devices with a focus on the microbiology space. Based in Guipry, France, NG Biotech is an in vitro diagnostics firm specializing in multiplex lateral flow technology.